Recent advances and perspectives in therapeutics for mpox

IF 2.5 4区医学 Q3 CHEMISTRY, MEDICINAL

Bioorganic & Medicinal Chemistry Letters Pub Date : 2025-07-11 DOI:10.1016/j.bmcl.2025.130330

Yaru Zhang , Tingnan Ma , Tao Yuan , Lingyu Su , Dongke Yu , Lei Zhong

{"title":"Recent advances and perspectives in therapeutics for mpox","authors":"Yaru Zhang , Tingnan Ma , Tao Yuan , Lingyu Su , Dongke Yu , Lei Zhong","doi":"10.1016/j.bmcl.2025.130330","DOIUrl":null,"url":null,"abstract":"<div><div>Mpox, a viral illness caused by the monkeypox virus (MPXV), has gained global attention due to its outbreaks worldwide in recent years. MPXV infections pose significant public health threats with notable transmission risks, yet specific antiviral treatments remain limited. Current therapeutic approaches primarily rely on smallpox vaccines and a limited number of broad-spectrum antiviral agents, such as tecovirimat, lacking specific drugs against MPXV. Thus, it remains a significant clinical need to develop anti-MPXV agents for the prevention and control of mpox outbreaks. In this review, we summarized the characteristics of MPXV in terms of viral structure, genome, and replication while reporting the recent progress in the development of small molecule anti-MPXV agents. Additionally, we discussed major obstacles in anti-MPXV drug development, including insufficient understanding of virus biology, the lack of reliable disease models, and limited resources for conducting large-scale clinical evaluations, and provided insights and perspectives for anti-MPXV therapies, with the aims of accelerating the development of effective treatments and contributing to preparedness against emerging orthopoxvirus threats.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"128 ","pages":"Article 130330"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X25002392","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Mpox, a viral illness caused by the monkeypox virus (MPXV), has gained global attention due to its outbreaks worldwide in recent years. MPXV infections pose significant public health threats with notable transmission risks, yet specific antiviral treatments remain limited. Current therapeutic approaches primarily rely on smallpox vaccines and a limited number of broad-spectrum antiviral agents, such as tecovirimat, lacking specific drugs against MPXV. Thus, it remains a significant clinical need to develop anti-MPXV agents for the prevention and control of mpox outbreaks. In this review, we summarized the characteristics of MPXV in terms of viral structure, genome, and replication while reporting the recent progress in the development of small molecule anti-MPXV agents. Additionally, we discussed major obstacles in anti-MPXV drug development, including insufficient understanding of virus biology, the lack of reliable disease models, and limited resources for conducting large-scale clinical evaluations, and provided insights and perspectives for anti-MPXV therapies, with the aims of accelerating the development of effective treatments and contributing to preparedness against emerging orthopoxvirus threats.

Abstract Image

查看原文本刊更多论文

m痘治疗方法的最新进展和展望。

猴痘是一种由猴痘病毒（MPXV）引起的病毒性疾病，近年来在世界各地暴发，引起了全球的关注。MPXV感染具有显著的传播风险，对公共卫生构成重大威胁，但具体的抗病毒治疗仍然有限。目前的治疗方法主要依赖于天花疫苗和有限数量的广谱抗病毒药物，如特可维林，缺乏针对MPXV的特异性药物。因此，开发抗mpxv药物预防和控制m痘暴发仍然是一个重要的临床需要。本文综述了MPXV在病毒结构、基因组和复制方面的特点，并报道了小分子抗MPXV药物的最新进展。此外，我们讨论了抗mpxv药物开发的主要障碍，包括对病毒生物学的了解不足，缺乏可靠的疾病模型，以及进行大规模临床评估的资源有限，并为抗mpxv治疗提供了见解和观点，旨在加速开发有效的治疗方法，并为应对新出现的正痘病毒威胁做出贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioorganic & Medicinal Chemistry Letters 医学-医药化学

CiteScore

5.70

自引率

3.70%

发文量

463

审稿时长

27 days

期刊介绍： Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.